GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OTCPK:OASMY) » Definitions » Cash And Cash Equivalents

Vivesto AB (Vivesto AB) Cash And Cash Equivalents : $0.42 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Vivesto AB Cash And Cash Equivalents?

Vivesto AB's quarterly cash and cash equivalents increased from Jun. 2023 ($0.29 Mil) to Sep. 2023 ($0.38 Mil) and increased from Sep. 2023 ($0.38 Mil) to Dec. 2023 ($0.42 Mil).

Vivesto AB's annual cash and cash equivalents increased from Dec. 2021 ($0.87 Mil) to Dec. 2022 ($0.91 Mil) but then declined from Dec. 2022 ($0.91 Mil) to Dec. 2023 ($0.42 Mil).


Vivesto AB Cash And Cash Equivalents Historical Data

The historical data trend for Vivesto AB's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivesto AB Cash And Cash Equivalents Chart

Vivesto AB Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.47 20.07 0.87 0.91 0.42

Vivesto AB Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.91 0.47 0.29 0.38 0.42

Vivesto AB Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Vivesto AB  (OTCPK:OASMY) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Vivesto AB Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Vivesto AB's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivesto AB (Vivesto AB) Business Description

Traded in Other Exchanges
Address
Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.

Vivesto AB (Vivesto AB) Headlines

From GuruFocus